Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518150 | 1.00 | KMT2A (0.70) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL27591796 | 0.85 | KMT2A (0.66) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL30162631 | 0.82 | KMT2A (1.00) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL377259 | 0.82 | KMT2A (1.00) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL8735682 | 0.81 | KMT2A (0.70) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL4358158 | 0.81 | KMT2A (0.70) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL120913 | 0.81 | KMT2A (0.70) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL13067261 | 0.81 | KMT2A (0.70) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL12413527 | 0.80 | KMT2A (0.64) | KMT2AALDH1A1MAPTTDP1GLA | |
| SCHEMBL6772400 | 0.78 | ALDH1A1 (0.48) | KMT2AALDH1A1MAPTTDP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-10-31 | — | — | US | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-01-04 | — | — | US | disclosed |
| EP-3247360-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | The Scripps Research Institute (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1042323-B1 | NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOD CONSEILS RECH APPLIC (FR) | 2002-04-10 | — | — | EP | disclosed |
| US-20010000521-A1 | New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2001-04-26 | — | — | US | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-1042323-A1 | NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999033829-A1 | NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | KMT2A 783/4885ALDH1A1 742/4885MAPT 1112/4885 |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | KMT2A 1296/4885ALDH1A1 353/4885MAPT 1981/4885 |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | KMT2A 1334/4885ALDH1A1 402/4885MAPT 1760/4885 |
| US-11560389-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | KMT2A 1334/4885ALDH1A1 402/4885MAPT 1760/4885 |
| US-20010000521-A1 | New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, TOP2B | KMT2A 3036/4885ALDH1A1 1774/4885MAPT 3218/4885 |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | KMT2A 783/4885ALDH1A1 742/4885MAPT 1112/4885 |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | SLC16A1, SLC16A3, SLC16A7 | KMT2A 787/4885ALDH1A1 651/4885MAPT 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.